ATLAS fair value
₹1,664
Above fair value · 16% premium
Ipca Laboratories share price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · National Stock Exchange of India · India
Prices as of Oct 26, 2026 · INR
₹1,664
Above fair value · 16% premium
51%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Ipca Laboratories's fair value at about ₹1,664 per share (reasonable range: ₹1,498 to ₹1,831). At ₹1,939, the stock trades 16% above it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Ipca Laboratories a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₹1,841 and ₹2,049; in 9 out of 10, between ₹1,675 and ₹2,252. Estimated annual volatility is 31%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Ipca Laboratories sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks IPCALAB.NSE has traded between ₹1,268 and ₹2,038. Today it is 4.9% below that high and 53% above its low.
On the business: net margin is 12.9%; it trades at 37.8 times earnings.
Its beta is 0.04: it tends to move less than the market.
Ipca Laboratories Ltd. is a prominent Indian pharmaceutical company that develops, manufactures, and markets a vast array of pharmaceutical products and active pharmaceutical ingredients (APIs).
Want to see everything about Ipca Laboratories?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About ₹1,664 per share according to ATLAS (reasonable range: ₹1,498 to ₹1,831). With the stock at ₹1,939, it is 16% above it.
51%: close to a coin flip. In half of the simulated outcomes, IPCALAB.NSE ends the month between ₹1,841 and ₹2,049.
Ipca Laboratories's market capitalization is ₹460B. Its price-to-earnings (P/E) ratio is 37.8: you pay ₹37.8 for each ₹1.00 of yearly earnings.
Yes. IPCALAB.NSE's current dividend yield is 1.21% at today's price (₹1,939).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy